SolaScren Lotion 8%+2%+3%+2%

Uses

This combination is used for-

• Normal skin types when exposed to intense sunlight
• Photodermatoses including those caused by radiotherapy
• Photosensitisation
• Solar urticaria
• Acute solar dermatitis
• Drug-induced photosensitivity
• Acute lupus erythematosus
• Herpes simplex
• Polymorphic light eruption
• Cutaneous albinism
• Vitiligo

SolaScren Lotion 8%+2%+3%+2% is also used to associated treatment for these conditions: SunburnSunburnBlisters, Dermatitis, Eczematous, Sunburn, Wounds, Abrasions, Dry, cracked skin, UV protection therapy

How SolaScren Lotion 8%+2%+3%+2% works

It blocks UVA I, UVA II, and UVB wavelengths, thereby limiting the impact of UV rays on skin. Diminish the penetration of ultraviolet (UV) light through the epidermis by absorbing UV radiation within a specific wavelength range. The amount and wavelength of UV radiation absorbed are affected by the molecular structure of the sunscreen agent.

Oxybenzone absorbs UV-A ultraviolet rays, preventing them from reaching the skin.

It is proposed that simultaneous contact of padimate O with keratinocytes can stimulate the diffusion through human epidermis. Upon photoexcitation, padimate O generates singlet oxygen and forms carbon-centred free radicals. While padimate O attenuates simple and repairable, UV-induced cellular damage, it may also increase complex chemical damage that is more difficult to repair by normal cells .

Diminish the penetration of ultraviolet (UV) light through the epidermis by absorbing UV radiation within a specific wavelength range. The amount and wavelength of UV radiation absorbed are affected by the molecular structure of the sunscreen agent.

Dosage

SolaScren Lotion 8%+2%+3%+2% dosage

Thislotion should be applied carefully and evenly on skin before sun exposure. Apply 45 minutes before swimming or sweat producing exercise. A single application may give day-long protection but the product should be re-applied during prolonged periods of sunning and after swimming or excessive sweating.

Side Effects

Signs of irritations (including erythema, burning or rash) may appear when applied to sensitive or broken skin.

Toxicity

A minimum toxic dose has not been established. Significant toxicity is not expected

Padimate O causes DNA strand breaks of cells under the epidermis in vitro . No LD50 value reported.

Rat - LD50 Intratracheal (>100ug/kg ) Effects: Structural or functional changes in bronchi and trachea. There is inadequate evidence in humans for the carcinogenicity of titanium dioxide. Cancer in experimental animals: There is sufficient evidence in experimental animals for the carcinogenicity of titanium dioxide. Overall evaluation: Titanium dioxide is possibly carcinogenic to humans (Group 2B).

Precaution

Application to broken skin should be avoided. Contact with the eyes and other mucous membranes should be avoided.

Interaction

There are no known drug interactions and none well documented.

Volume of Distribution

No pharmacokinetic data available.

Six hours after titanium dioxide was administered to rats through IV injection at 250 mg/kg body weight, the highest concentration appeared in the liver; after 24 hours, the highest concentration was detected in the celiac lymph nodes, which filter the lymph from the liver.

Elimination Route

Padimate O is capable of human skin penetration .

When male and female rats were fed a diet containing titanium dioxide (100 g/kg) for a period of about 32 days, a significant retention of titanium of 0.06 and 0.11 mg/kg wet weight was found only in the muscles; no retention was observed in the liver, spleen, kidney, bone, plasma, or erythrocytes

Half Life

No pharmacokinetic data available.

The kinetics of TiO2 elimination in the rat lung following its deposition after 7 hr exposure at 10 and 50 mg/cu m were determined for periods up to 140 days...The retention half-time was 14 days for the first clearance phase and 88 days thereafter.

Clearance

No pharmacokinetic data available.

The clearance of titanium dioxide from the lungs was studied in rats after inhalation of 15 or 100 mg/cu m. The average median aerodynamic diameter of the titanium dioxide particles was 1.48 um. After a single exposure, about 40-45% of the deposited particles were cleared from the lung in 25 days. At 15 mg/cu m, 0.7% was found in the hilar lymph nodes indicating penetration of titanium dioxide particles from alveoli into the lymphatic system and partial clearance by the lymphatic route. The clearance rate was similar after intra-tracheal administration of titanium dioxide. At an exposure of 100 mg/cu m, the clearance rate decreased drastically. /Other researchers/ demonstrated the presence of titanium dioxide in the lymphatic systems of 3 workers employed in processing titanium dioxide pigments.

Elimination Route

In vivo studies show oxybenzone is abosorbed transdermally (through the skin) and is excreted in the urine.

No pharmacokinetic data available.

The kinetics of TiO2 elimination in the rat lung following its deposition after 7 hr exposure at 10 and 50 mg/cu m were determined for periods up to 140 days.The retention half-time was 14 days for the first clearance phase and 88 days thereafter.

Pregnancy & Breastfeeding use

This lotion should only be used if the anticipated benefits outweigh the risks.

Contraindication

Known hypersensitivity to any of its components.

Innovators Monograph

You find simplified version here SolaScren Lotion 8%+2%+3%+2%